1st International consensus guidelines for advanced breast cancer (ABC 1).
about
Combination versus sequential single agent chemotherapy for metastatic breast cancerTreatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesImpact of molecular subtypes on metastatic breast cancer patients: a SEER population-based studyESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013Integrating genetic and genomic information into effective cancer care in diverse populations.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.Radiotherapy in patients with distant metastatic breast cancer.Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in TurkeyAssessing quality of life in patients after partial laryngectomy.Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacyMolecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?Use of bevacizumab as a first-line treatment for metastatic breast cancer.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOGPrognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?Essential medicines for breast cancer in low and middle income countries.Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in EuropeEffects of a nurse-led medication self-management programme in cancer patients: protocol for a mixed-method randomised controlled trial.Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis.Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statementHepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated PatientsHormonal therapies in young breast cancer patients: when, what and for how long?Prognostic factors related to surgical outcome of liver metastases of breast cancer.Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Usefulness of traditional serum biomarkers for management of breast cancer patients.Primary surgical treatment of locally advanced breast cancer in low resource settings.Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
P2860
Q24201726-BCA7BE23-8592-47C9-807D-CDEF3C8F5645Q26741153-66C8EDE6-518D-4D56-AEC9-6A27A0C0A5B0Q26785496-89891959-DC30-495B-91AA-43BCDB8F64FCQ28080469-ECEE840E-DBFB-4F8C-BD7E-937221AFF2B4Q29248323-EDDA8E21-5C3A-431D-AF61-BD046CD1C3BAQ30317067-F9E4A326-630E-46E6-8178-4464664346AAQ30317569-9C2A874B-879C-4DA4-847C-DB15AA7E0F43Q33597778-BE012CBD-8864-426F-B485-D42D78DFA32CQ33632205-4E0EC99A-E964-48EE-B03F-1403DB6FF699Q33759443-1C4DEE3E-C5D5-434A-A11F-278DB5AC2245Q33777431-0EB7D779-6180-4B41-9FBA-4583EB02B044Q34042768-84BE7B91-AD44-439A-9F1A-B8F71F7F593AQ34130140-9900BF92-509C-46BC-852E-25302C94022EQ34130479-85764465-C931-4B5F-8F8C-1B0F43C41968Q34361487-DB131A8A-DACE-437D-93E6-9BB714A5C8D8Q34499626-8D7625DE-708F-486E-9548-92A9AE2513A8Q34723641-62A13C77-E4C4-4351-86B5-EE6EBCE5339FQ35000278-9EA42C52-1118-41EB-A5B7-5BF312FCFAADQ35164247-1D1CF143-E740-4B1D-9895-4E175044119EQ35445151-A1F5EAC7-8D76-44E2-AC77-CCA3D94CE795Q35507680-633EB1C4-D6D3-4E67-9877-BBE7AF24CE17Q35611919-31A9B7B1-D930-4CF0-BACC-2116EEAF0CAEQ35677925-611A41C9-32D1-4B9D-87CA-BAE65B9ACB81Q35748465-70A13D65-0DB0-4873-B6A6-57316B2CFDBFQ35754251-862CE763-E397-424B-9CC9-E5680DF31610Q35820168-143C95F6-47CA-4103-9908-6BC5320EECF0Q35917917-D0342285-C8CB-49A0-89BD-43BA0EAD50DEQ36551186-69167652-0A78-4DB3-A373-2E4AFBF02677Q36568571-F0CE3C00-83EF-4E3F-842C-8A8B815B46F3Q36757904-CEA035C7-FD13-416E-92AC-9B839415B574Q36963393-CADE32FD-9B00-4276-8B79-E5AB479A1783Q36998135-652AC188-BAC6-4B14-8CAC-C5F9E497D27DQ37169342-C7BE5E1C-118A-4467-8D52-D0730D3CA220Q37236305-D64FD6B3-4519-4437-96D6-DD150E10296DQ37375636-935B4E63-043E-4E1E-8208-5A4923775998Q37386094-0AEF561D-7AE7-4CBD-B66A-8E8AB69B7B1FQ37470730-BF2FF0CD-45BD-4CCE-94EE-26C7D1EBE71AQ37501868-1AFD5CDC-AF75-45F8-82C3-E2DA5BE185E2Q37534910-09D9153D-02EF-49EA-8FBD-F8CA63373B03Q37635256-BC0C8307-FD6F-4EBF-8A70-65C61DC633EA
P2860
1st International consensus guidelines for advanced breast cancer (ABC 1).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
1st International consensus guidelines for advanced breast cancer (ABC 1).
@en
1st International consensus guidelines for advanced breast cancer
@nl
type
label
1st International consensus guidelines for advanced breast cancer (ABC 1).
@en
1st International consensus guidelines for advanced breast cancer
@nl
prefLabel
1st International consensus guidelines for advanced breast cancer (ABC 1).
@en
1st International consensus guidelines for advanced breast cancer
@nl
P2093
P50
P1433
P1476
1st International consensus guidelines for advanced breast cancer (ABC 1)
@en
P2093
A Goldhirsch
C Thomssen
P304
P356
10.1016/J.BREAST.2012.03.003
P50
P577
2012-03-16T00:00:00Z